Citation

Cheng H., Nair S., Murray B., Almaden C., Bailey S., Baxi S., Behenna D., Cho-Schultz S., Dalvie D., Dinh D., Edwards M., Feng J., Ferre R., Gajiwala K., Hemkens M., Jackson-Fisher A., Jalaie M., Johnson T., Kania R., Kephart S., Lafontaine J., Lunney B., Liu K., Liu Z., Matthews J., Nagata A., Niessen S., Ornelas M., Orr S., Pairish M., Planken S., Ren S., Richter D., Ryan K., Sach N., Shen H., Smeal T., Solowiej J., Sutton S., Tran K., Tseng E., Vernier W., Walls M., Wang S., Weinrich S., Xin S., Xu H., Yin M., Zientek M., Zhou R., Kath J.: Discovery of 1-{(3<i>R</i>,4<i>R</i>)-3-[({5-Chloro-2-[(1-methyl-1<i>H</i>-pyrazol-4-yl)amino]-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl}oxy)methyl]-4-methoxypyrrolidin-1-yl}prop-2-en-1-one (PF-06459988), a Potent, WT Sparing, Irreversible Inhibitor of T790M-Containing EGFR Mutants. Journal of Medicinal Chemistry, Volume 59 (5), 2016

Authors

Hengmiao Cheng, Sajiv K. Nair, Brion W. Murray, Chau Almaden, Simon Bailey, Sangita Baxi, Doug Behenna, Sujin Cho-Schultz, Deepak Dalvie, Dac M. Dinh, Martin P. Edwards, Jun Li Feng, Rose Ann Ferre, Ketan S. Gajiwala, Michelle D. Hemkens, Amy Jackson-Fisher, Mehran Jalaie, Ted O. Johnson, Robert S. Kania, Susan Kephart, Jennifer Lafontaine, Beth Lunney, Kevin K.-C. Liu, Zhengyu Liu, Jean Matthews, Asako Nagata, Sherry Niessen, Martha A. Ornelas, Suvi T. M. Orr, Mason Pairish, Simon Planken, Shijian Ren, Daniel Richter, Kevin Ryan, Neal Sach, Hong Shen, Tod Smeal, Jim Solowiej, Scott Sutton, Khanh Tran, Elaine Tseng, William Vernier, Marlena Walls, Shuiwang Wang, Scott L. Weinrich, Shuibo Xin, Haiwei Xu, Min-Jean Yin, Michael Zientek, Ru Zhou, John C. Kath

Journal

Journal of Medicinal Chemistry

Year

2016

DOI

10.1021/acs.jmedchem.5b01633

Machine-readable

REST APIRDF